For LPs
Back the layer of biology that everything else depends on.
We invest where deep technical diligence creates an edge — and where our partners have already built and exited companies.
The case
Why this fund, and why now.
Tools have a shorter path to revenue
Instruments, reagents, and software sell to researchers years before a therapeutic reaches the clinic — shortening the distance between our first check and real commercial signal.
Exposure to every therapeutic wave
Whatever modality wins, it runs on tools. Our portfolio benefits from growth in multi-omics, spatial biology, cell and gene therapy, and AI-driven discovery at once.
Founder-operators sourcing at the source
We see companies at formation through UCSD, Salk, and the San Diego tools ecosystem — often before a deck exists.
A track record that predates the fund
Our partners co-founded NanoCellect, Arima Genomics, Defined Bioscience, and Mesa Biotech, with acquisitions by Thermo Fisher and Dexcom.
At a glance
Fund profile
- Strategy
- Pre-seed and seed
- Focus
- Life science tools, platforms, AI x Bio
- Geography
- San Diego–anchored, US-wide
- Support model
- Capital, coaching, commercial strategy
Fund size, terms, and performance figures are shared privately with qualified investors. Nothing on this page is an offer to sell securities.
Request our LP materials
Tell us a little about your mandate and we'll follow up with our deck and a time to talk.